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Juvenile chronic myelogenous leukemia (JCML) is a myeloproliferative disease in which morbidity and mortality are primarily caused by nonhematopoietic organ failure from myelomonocytic infiltration or by failure of the normal bone marrow. Morphologic evidence of maturation arrest, karyotypic abnormalities, and progression to blast crisis are infrequent events. Viral infections and other reactive processes can initially mimic the clinical course of JCML, creating diagnostic problems. Because of the rarity of JCML and technical limitations, formal clonalii studies have not been reported previously. Nine female JCML patients were identified by clinical criteria, characteristic 'spontaneous' in vitro cell growth, and negative cultures and titers for various viral agents. Peripheral blood and bone marrow samples were obtained at the time of diagnosis for cell separation and UVENILE CHRONIC myelogenous leukemia (JCML) is a rare myeloproliferative disorder of early ~hildhood,'.~ which is distinct from adult type, Philadelphia chromosome positive CML. JCML is characteristically associated with moderate leukocytosis, monocytosis, thrombocytopenia, hepatosplenomegaly, elevated fetal hemoglobin for age, eczematous rash, and occasional hypergammaglobulinemia. There is a high prevalence of morbidity due to failure of the normal bone marrow (BM) or to infiltration of monocytic cells into pulmonary, gastrointestinal, or other tissues leading to hemorrhage and/or organ dysfunction. Mortality often occurs because of irreversible organ damage or infection.
The clonal origin from a malignant hematopoietic progenitor cell is a basic tenet for the definition of the myeloid leukemias?" Other supporting features include the presence of mitotically active myeloid cells in nonhematopoietic tissues, the presence of characteristic chromosomal abnormalities, morphologic evidence of maturation arrest, and the transplantability of similar-appearing myeloid leukemias in animals.' JCML fulfills only one of these criteria, the presence of myeloid cells in nonhematopoietic tissues. There is no maturational arrest evident, no consistent chromosomal abnormalities, and, apart from a recent report in a severe combined immunodeficient (SCID) mouse model? there is no true animal model to test for transplantability. In fact, transformation to an acute leukemic blast crisis occurs in less than 20% of JCML cases. Although the clonal nature of JCML could be inferred from several reports of small numbers of patients who have had chromosomal abnormalities,""' the paucity of cases as well as technical problems with clonality assays have prohibited accurate assessment of clonality. JCML may be misdiagnosed because of similar clinical presentations from viral infection^'^." or other myeloproliferative disorders. Therefore, one could argue that JCML might be initially a reactive proliferative disorder of mature monocytes with malignancy occumng later, in a minority of patients, because of a second event. Hence, determining clonality is critical to understanding the pathophysiology of this disorder.
Of the several methods for assessing clonality of hemato- RNA and DNA isolation. To assess clonality, X-chromosome inactivation patterns were evaluated using three diff.rent, recently developed polymerase chain reaction-based clonality assays. All nine female JCML patients showed evidence for monoclonal origin of mononuclear cells at the time of diagnosis. Cell separation studies further traced the monoclonal origin back to at least the most primitive myeloid progenitor cell. Reversion to a polyclonal state was demonstrated after bone marrow transplant and also in one patient following treatment with 13-cis retinoic acid. This demonstration of clonality in JCML delineates it from the reactive processes and provides a basis for molecular genetic strategies to identify causally associated mutations.
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poiesis, the most widely used are based on Lyon's hypothesis of X-chromosome inactivation.I8 This states that most of the X-chromosome genes are transcribed in each female somatic cell exclusively from the active X-chromosome, which is either maternally or paternally derived. This process, which occurs in early embryogenesis, results in the terminal inactivation of most of the genetic material on the other X-chromosome. Because it is a random event, normal polyclonal female tissue is mosaic, in contrast to clonal tissue which contains cells bearing the same active X-chromosome. The initial clonality studies in malignancy took advantage of this event by using analysis of isoenzyme expression for glucose-6-phosphate dehydrogenase (G6PD In this report, our approach using multiple clonality assays obviated the above-described limitations in each assay, and showed evidence of clonality in JCML at the time of diagnosis.
MATERIALS AND METHODS
Peripheral blood (PS) and BM samples from untreated, newly diagnosed female JCML patients were used in this study. Diagnostic criteria for JCML included leukocytosis with monocytosis, hepatosplenomegaly, absence of chromosomal abnormalities, less than 25% marrow blasts, negative viral titers and cultures, and in vitro studies showing 'spontaneous' colony growth and selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) as described previously." Patients with monosomy 7 were excluded. With parental consent and the approval of the respective Institutional Review Boards, PB andor BM aspirate samples were collected into preservative-free heparin (100 U/mL) and shipped at ambient room temperature overnight for analysis. Some of the studies described below were performed at two institutions, with some differences in methods. Both sets of results were compared for confirmation.
Cell Separation and RNA and DNA Isolation
Neutrophils (PMN) cells were separated from mononuclear cells (MNC) by density gradient centrifugation on Ficoll-Paque (Pharmacia, Uppsala, Sweden) or Histopaque-l077 (Sigma, St Louis, MO) depending on the institution. PMNs were isolated in the erythrocytic phase (>95% purity by Wright stain) after hypotonic lysis of the red blood cells (RBCs). PMNs were subsequently lysed with Triton X-100 (Sigma) lysis solution (0.32 mol/L sucrose; 10 mmollL TRIS pH 7.5; 5 mmol/L MgCI2; 1% Triton X-100). Nonadherent cells in the MNC were isolated from adherent cells by different methods. In the first, performed at the University of Alabama at Birmingham (UAB), after Histopaque separation MNC were washed three times with Hanks' balanced salt solution (HBSS) (GIBCO, Grand Island, NY) and then plated in HBSS with 13% human AB serum. After three successive adherence depletion steps as previously described," nonadherent cells (progenitor and lymphocyte-rich) were harvested and lysed in Triton X-100 buffer. Adherent cells (monocytes) were isolated using a rigorous adherence, washing, and scraping protocol as described previously3* and lysed with Triton X-100. In the second method, performed at the Brigham and Women's Hospital, MNC isolated from Ficoll-Paque were washed three times with Iscove's Modified Dulbecco's Medium (IMDM)/2% fetal calf serum (FCS) (GIBCO) and plated on Lux dishes (Nunc Inc. Naperville, IL) in IMDM/10% FCS at 37°C overnight in a humidified incubator with 5% COz. Nonadherent cells were procured and lysed in Triton X-100. Adherent cells were recovered by scraping the Lux dishes with subsequent lysis in Triton X-100. Platelets were isolated by differential centrifugation to obtain platelet-rich plasma, then pelleted and lysed with Triton X-100.
RNA Isolation und Preparation
Total reticulocyte RNA was isolated by selectively lysing peripheral blood erythrocytes, then isolating RNA as described by Goosens and Kan" with the modification of an additional purification of the acid RNA precipitate by the guanidine HCI-phenol method." The RNA from the other cells studied was prepared by using the guanidine HC1-phenol method.34 The RNA aliquots were used for preparations of cDNA template by reverse PCR reaction from the total cellular RNA by random priming.35
DNA Isolation and Preparation
All isolated cell populations were digested with SDS (5%)/proteinase K (2 mg/mL) buffer at 37°C for 24 
Flow Sorted Cells Analysis

Lineage Depletion
To remove mature cells from BM samples and to enrich for hematopoietic progenitors, we performed negative selection as described p r e v i o~s l y .~~ Briefly, nonadherent cells were concentrated by centrifugation and resuspended in 1 pL FCS/106 cells. Antibodies against use only. FACS. Immunofluorescence analysis and cell sorting was performed on a FACStar Plus cell sorter (Becton Dickinson) with a Hewlett Packard computer system (Palo Alto, CA). FITC and PE fluorescence were excited using an Innova 90 argon laser (Coherent, Palo Alto, CA) tuned at a wavelength of 488 nm with 200 mW power output. For analysis and sorting, the Consort 32 operating system (Hewlett Packard) and LYSIS I1 software (Becton Dickinson) was used. Sort windows were drawn on the CD34 (FITC') and CD38 (PE-) BM population. Lineage positive cells were also analyzed and sorted using a window for CD14' cells and the CD14-BM population.
Clonality Assays Based on Differential DNA Methylation of X Chromosomes
HUMARA Clonality Assay
The HUMARA assay was recently developed" and was performed with minor modifications and is explained in detail in a recent publication. '8 Quantitarion of alleles. Dried gels were exposed to a phosphor screen for 24 hours, then scanned on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The ratio between the two X-linked alleles was measured using the ImageQuant software (Molecular Dynamics). The allele ratio is the ratio between the two X-linked alleles in a given sample. The corrected ratio (Cr) is the allele ratio of the digested sample divided by the allele ratio of the nondigested sample of the same specimen. This ratio compensates for potential preferential amplification of the one active allele.
PGK-PCR Clonality Assay (PPCA)
This technique has been described in detail e l s e~h e r e .~~.~* As a further confirmation of findings, this assay was performed by both groups in this report with minor differences in technique as described below. In the PPCA performed at the Brigham and Women's Hospital, genomic DNA was initially digested with HpaII as described for the HUMARA clonality assay with the omission of the RsaI enzyme. A nondigested sample was used as an auto-control.
PCR amplification of the PGK locus. A PCR mix containing 8 pL of 1OX buffer (same as above), 8 pL of dNTP (200 pmoVL each), 4 pL (20 pmol) each of primer 2A and 2B37, 0.2 pL (1 U) of Taq polymerase (Cetus, Norwalk, CT), and 52 pL of dHzO was added to the microfuge tube used for the digestion. Tubes were overlaid with 50 pL of mineral oil.
Amplifcation parameters. Denaturation occurred at 94°C for 3 minutes, then 50 cycles of PCR with the following parameters: 1 minute at 94°C; 1 minute 45 seconds at 58°C; 2 minutes 45 seconds at 72°C.
BstXI secondary digestion. Twenty-three microliters of the PCR reaction was added to 1 pL of H buffer (Boehringer Mannheim) and 10 U of BsfXl (Boehringer Mannheim) in a new tube and digested at 45°C for 4 to 12 hours. An aliquot of 15 pL from the digestion reaction was run on a 2% agarose gel stained with ethidium bromide. The PPCA performed at UAB was quite similar, except for the following modifications. In the initial Hp11 digestion, samples were incubated at 37°C for 24 to 36 hours, then heat inactivated for 3 minutes at 100°C. A Perkin-Elmer Cetus thermal cycler (Norwalk, CT) was used and the Taq polymerase was purchased from Promega (Madison, WI). Two amplifications were used with internal "nested" primers (Research Genetics, Huntsville, AL) exactly as described previouslyg7 except that 40 cycles were used for each amplification instead of 60 cycles.
Polyclonal samples have both the 530-and 433-bp bands with a ratio between the two alleles close to 3: 1 because of heteroduplexing between the BstX1-positive strand and the BstX1-negative strand during PCR. These heteroduplexes do not digest with BsfXl and artifactually increase the relative proportion of the 530-bp allele. A sample is judged to be polyclonal if both alleles are visualized, whereas a clonal sample will either have only one of the two alleles present, or will demonstrate a major shift in the 3: 1 ratio after BstXl digestion. There was good concordance of results and conclusions in the PGK-PCR assays performed at the two institutions.
Clonality Assay Based on the Detection of a Transcriptional Polymorphism on the Active X Chromosome
G6PD C T Polymorphism Clonality Assay
These analyses use detection of an active X chromosome transcriptional polymorphism by amplification of the polymorphic region of the G6PD gene by PCR, and then detection of the polymorphism by the ligase detection reaction (LDR) using thermostable ligase that covalently binds with adjacent DNA oligonucleotides, provided they are perfectly complementary to target DNA in the region of ligaor a cDNA template prepared by reverse transcription-PCR reaction from total cellular RNA.35 The LDR assay was performed as de~cribed,~'.'" with the following modifications. The target consists of 10 ng of DNA and NAD+ is at 1 mmol/L. A cloned thermostable ligase:' a kind gift from Dr F. Barany (New York, NY), was diluted in 10 mmol/L Tris HCI pH 8.0 in 50% glycerol containing 0.5 mmoll L EDTA, I mmoVL dithiothreitol, 100 pg bovine serum albumin (Fraction V), and 0.1% Triton X-100. The PCR primers for amplification of the genomic DNA are as previously p~blished.~"~' Thirty cycles of ligation reaction are used at 1 minute at 94°C and 4 minutes at 65°C. The reaction products are separated on a 10% polyacrylamide gel containing 7 mol/L urea and detected by autoradiography. For more details justifying the design and principles of LDR, refer to the original method des~ription.~~~"'~'' Evidence for clonality is based on the loss of either the T allele (a 46-bp nucleotide fusion product) or the C allele (a 44-bp nucleotide fusion product).
tion.2Y.30.39 LDR analysis was performed either using a genomic DNA Table 1 depicts demographic information for the nine JCML female patients used in this study, as well as the clonality assays used for each patient. The patients are numbered according to the JCML registration system at UAB. One of the nine female JCML patients, 522, proved informative for a transcriptional polymorphism at the C T locus in the exonic nucleotide no. 13 1 1 of the G6PD gene. Using the ligase chaiddetection reaction, cDNA templates prepared from total cellular R N A were analyzed from isolated populations of mononuclear cells, granulocytes, monocytes, platelets, and reticulocytes from the patient. The results (Fig 1) use 
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Abbreviations: U, unsatisfactory (data not evaluable because of insufficient amplification); H, homozygote (patient sample not informative by this assay); NT, not tested; M, monoclonal-patient sample yielded sufficient amplification, was heterozygote at the locus used, and showed monoclonal derivation of cells.
All had varying degrees of monocytosis.
show that all of these separate cell populations were clonally derived at the time of diagnosis in patient 522 because all cells expressed only the C allele (44-bp product). This patient was subsequently treated with 13-cis retinoic acidJ2 but unfortunately had progressive disease and succumbed. Of the other eight JCML patients, clonality information was obtainable by the HUMARA assay for patients J9, J IO, 515, 535, and 539, whereas the PGK-PCR assay provided information on patients J9, J IO, JI 5, 520, 53 I , 535, 539, and 540 ( Table l) . All of these tests showed monoclonal derivation of cells at the time of diagnosis in all of these patients. Figure 2 shows a composite HUMARA assay demonstrating clonality in four representative JCML patient mononuclear samples at the time of diagnosis, before initiation of any therapy. The process of amplification of short tandem repeats gives rise to a phenomenon known as shadow banding, supposedly caused by slippage of the Taq polymerase; thus, the presence of 3 to 4 bands in the HUMARA
bp 44 bp
assay. The ratio analysis in the HUMARA assay, as analyzed on the Phosphorlmager, showed that greater than 95% of cells were clonally derived. Therefore, very few normal hematopoietic elements remained at the time of diagnosis. Figure 3 shows a composite PGK-PCR assay for three other representative JCML patients at the time of diagnosis. Because both the HUMARA and the PGK-PCR assays are also PCR-based, they are, like the ligase chaiddetection reaction, sensitive assays for clonality assessment from minute cell populations, and in addition are highly informative.
One patient, J35, was analyzed for clonality at several timepoints through the course of her disease (Fig 4) . both by HUMARA and by PGK. After diagnosis and initial assessment, she was treated with 1 3 4 s retinoic acid for several months according to Pediatric Oncology Group protocol no. 9265."' Concurrent with a partial response to retinoic acid, there was evidence for some reversion to a polyclonal state (Figs 5 and 6 ). However, because of increasing leukocytosis, Fig 1. LDR analysism of the polymorphic GGPD no. 1311 locus using a cDNA template prepared by reverse PCR reaction from total cellular RNA of JCML patient, 522. In the C/T control, the target DNA is from an individual heterozygous for the C and T polymorphisms. Negative control represents sham experiment without added template. In this assay, the T allele is detected by a 46-nucleotide fusion product, whereas the presence of the C allele results in the synthesis of a Wnucleotide fusion product. Evidence for clonality is based on the loss of either allele. DNA samples were analyzed using a PCR assay as described with the human androgen-receptor locus. Lanes +, PCR after Hpall predigestion; lanes -, PCR without predigestion. Clonality is shown by the presence of only the active X allele after digestion lie, presence of lower set of bands but loss of upper bands in + lanes). The process of amplification of short tandem repeats gives rise t o a phenomenon known as shadow banding, supposedly caused by slippage of the Taq polymerase. Thus, the presence of 3 t o 4 bands in the HUMARA assay.
retinoic acid was discontinued and she received an allogeneic BM transplant (BMT). Unfortunately, she failed to engraft (data not shown) and within months had clinical re-emergence of JCML, concomitant with a recrudescence of clonal hematopoiesis (Fig 5) . At this timepoint, cells isolated by lineage depletion and flow sorting showed that both CD14' and CD14.-fractions were clonal (Fig 7) . Further cell separation and isolation demonstrated that early stem and progenitor cells, marked by CD34', CD38- (Fig 8, region 2) were also clonal by HUMARA analysis. This provided excellent correlation with the results in patient 322 (Fig 1 ) from the ligase chaiddetection reaction, showing that all cell populations derived from a cell as primitive as at least the myeloid stem cell level were clonal. Although these data imply that lymphocytes are also clonal, indicating that JCML is a pluripotent stem cell disorder, definitive lymphocyte separation and clonality assessment are yet to be performed on future samples. Two other patients in this study, J9 and J15, had clinical responses to retinoic acid. However, the data in these two cases were inconclusive in regard to a significant shift toward polyclonality after retinoic acid therapy (data not shown). Patient JI 5 has subsequently received an allogeneic BMT. Since the transplant she has no evidence of disease and demonstrates a polyclonal pattern by PGK-PCR assay, in contrast to the clonal pattern at diagnosis (data not shown).
In all of the above clonality assays, we attempted to use somatic controls to address extreme skewing of LyonizationJ3 when possible. Many of the samples were previously stored specimens and thus other tissue not available. Patient 535 had skin tissue available and did not show skewing in the HUMARA assay (Fig 6) or in the PGK-PCR assay ( Fig  5) . Further, the incidence of excessive skewing appears lower in children." Excessive skewing to the degree necessary to give the results in Fig 1 has not been observed in normals with the LCR/LDR assay.44 Finally, the ultimate control to rule out this phenomenon was observed in JCML patient 535 when a reversion from clonality to polyclonality was observed.
DISCUSSION
JCML is an interesting disorder that occurs in early childhood. Most patients are ages 3 to 24 months at diagnosis, though it is seen in patients up to 4 years of age. It is rarely seen in the neonatal period and thus not considered a congenital disease. The disease is typically more fulminant than most other chronic myeloproliferative disorders with a median survival of less than 10 months."' JCML can pose a diagnostic dilemma for pediatricians. Early phase JCML can clinically resemble infection from Epstein-Barr virus,16 cyt~megalovirus,'~ or other agents, and it can be difficult to distinguish from other myeloproliferative syndromes because the myelomonocytic proliferation is morphologically normal, as is the karyotype. There is a male predilection of approximately 2:1, similar to the pattern in myeloproliferative syndrome with monosomy 7, but the diseases appear to be Because JCML phenotypically resembles certain histiocytic syndrornes,4' one could envision that the disease is confined to the monocytic lineage. Therefore, these clinical aspects of JCML, especially similarity to other diseases, raise the question as to whether this is a clonal versus a polyclonal process, especially because clonality analysis in other myeloproliferative disorders has yielded variable r e s~l t s .~~,~~
The somatic mutation theory of carcinogenesis posits that tumors are the result of a monoclonal expansion of a single cell with selective growth advantage because of acquired somatic mutation(s). Thus, the assessment of the clonal derivation of cells is an essential element of the characterization and definition of a malignancy. The assays available pres-BUSQUE ET AL entiy for clonality assessment all suffer from Iirnitatiotx2' The most widely used assays depend on differential methylution patterns between the active and inactive X-chromosomes at various polymorphic loci. Limitations may arise due to either low levels of informativeness at the particular locus or due to unreliable methylation patterns. Of the available probes, the HUMARA gene is highly informative and appears to have reliable differential methylati~n.'~.'' A different, recently developed, clonality assay uses the transcriptional analysis of the active X chromosome based on a DNA exonic polymorphism detected by the ligase chain reaction and circumvents the methylation limitation.2"'" But the polymorphic locus presently used for this assay is limited by modest informativeness. Other exonic polymorphic loci with higher levels of heterozygosity are being tested currently. (J.T.P., unpublished observations, September 1994). Therefore, if one wants to examine the clonal nature of a particular disorder from limited numbers of female patients, the most logical approach may be to use several of the assays to corroborate results. This was the approach used in the present study to prove the clonal nature of hematopoiesis at the time of diagnosis in JCML.
Our results indicate that the hematopoietic mononuclear progenitor and stem cells are clonal at the time of diagnosis in 9/9 of the JCML patients tested. Furthermore, we show in one patient that CD34'. CD38-early progenitor cells are clonally derived when examined by the HUMARA assay. as are the reticulocytes, platelets, monocytes, and granulocytes in a second patient examined by the ligase chaiddetection reaction. These data definitively show that JCML is not a pure monocytic disorder. Rather, it is the result of a clone arising from the earliest myeloid stedprogenitor cell, or possibly a more primitive stem cell. It could potentially arise from different levels of early progenitors in different patients, as noted in some cases of essential thrombocythemia." Furthermore, it remains unclear whether the mutation(s) causing JCML can confer self-renewing potential on the myeloid stem cell, a feature not thought to be present at this level in normal hematopoiesis.
Another intriguing preliminary finding from the clonality assays in this study is the partial reversion to polyclonality demonstrated in one patient, following a partial clinical response to 13-cis retinoic acid (CRA) therapy? JCML patients' response to chemotherapy is generally BMT appears to be curative in some, but is hindered by a high relapse rate.s2 CRA therapy has shown some promise in a pilot trial4' and is under further evaluation in a formal phase I1 protocol (Pediatric Oncology Group no. 9265). Patient 535 in this study demonstrated re-emergence of polyclonal hematopoiesis with CRA therapy, whereas the evidence in two other patients was inconclusive (data not shown). This phenomenon is being further investigated through the phase JCML monocytes is inconsistent." Rather, the consistent Removal of monocytes, and potentially other cells, by adherfinding is one of selective hypersensitivity by the nonadherence to plastic before culture of the cells abrogates the 'sponent progenitors to GM-CSF, but not to interleukin-3 (IL-3) taneous' growth.3' However, it is not a truly paracrine-driven or granulocyte-CSF (G-CSF cent reports have shown allelic loss of the NFI gene in some NF-1 patients with JCML,58 and N-rus mutations in other JCML patients." Both NFI loss and N-ras mutations may activate the Ras signal transduction pathway. GM-CSF is also known to activate Ras-GTP;" an intriguing potential connection considering the GM-CSF hypersensitivity of JCML cells. Yet, RAS mutations are observed in a broad spectrum of neoplasms. Thus, determining whether RAS mutations are involved in the pathogenesis of JCML will require further study.
In summary, JCML is a clonal disorder at the time of use only.
For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From diagnosis evolving from an abnormal myeloid stem cell, or possibly an earlier level. But is it a malignant process from the start? The Knudson "two-hit" model of malignancy6' proposes that the first "hit" gives a proliferative advantage to a clonally derived population that may be phenotypically and karyotypically normal, such as JCML at diagnosis. The second "hit" then leads to the malignant phen~type.'~ One could postulate that early phase JCML is the consequence of a single mutation conferring a proliferative/survival advantage. But because of marked monocytosis, JCML patients suffer earlier and greater morbidity than in other myeloproliferative disorders because excessive monocyte numbers create more problems than do excessive RBCs (ie, polycythemia vera) or platelets (ie, essential thrombocytosis). If so, then why is JCML so much more difficult to control with chemotherapy than these disorders? The answers to these and other questions may come from molecular genetic strategies aimed at identifying mutations responsible for the aberrancies in the signal transduction pathways leading to cytokine hypersensitivity, such as GM-CSF in JCML, and insulinlike growth factor-I (IGF-l) hypersensitivity in polycythemia vera."
analysis of the active X-chromosome in normal and clonal hematopoiesis. 
